Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb shared new data from its targeted protein degradation platform at the 2025 European Hematology Association/EHA Annual Congress, held in Milan from June 1 to 15.

These presentations featured updated clinical findings for investigational oral CELMoD agents (mezigdomide, iberdomide, golcadomide) and a first-in-class oral BCL6 ligand-directed degrader (BMS-986458), all of which showed potential to address unmet medical needs in blood cancers. The promising early results are driving multiple Phase 3 studies for mezigdomide, iberdomide, and golcadomide, with projected data readouts spanning from 2025 to 2030.

A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution.

Mezigdomide is an oral drug used for relapsed/refractory multiple myeloma (RRMM), trials for which showed significant patient responses. The most common severe side effect reported was neutropenia, a low count of a type of white blood cell. Another oral drug, iberdomide, was tested in 18 patients with newly diagnosed multiple myeloma. The results were very positive, with 88.9% of patients responding to the treatment. Golcadomide showed promising results in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma. The most common severe side effects were neutropenia and anemia.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.